Allogene Therapeutics (ALLO) News Today $1.16 +0.07 (+6.42%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period BNP Paribas Financial Markets Boosts Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)BNP Paribas Financial Markets lifted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 1,732.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 849,658 shares of the company's stock after puMay 20 at 3:47 AM | marketbeat.comResearch Analysts Set Expectations for ALLO Q2 EarningsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at William Blair boosted their Q2 2025 earnings estimates for Allogene Therapeutics in a research report issued on Wednesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings per sMay 20 at 2:08 AM | marketbeat.comWilliam Blair Issues Optimistic Estimate for ALLO EarningsMay 20 at 2:05 AM | americanbankingnews.comRaiffeisen Bank International AG Invests $903,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Raiffeisen Bank International AG purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 430,000 sharMay 19 at 6:05 AM | marketbeat.comCitigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock PriceMay 18 at 1:23 AM | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Downgraded by Citizens Jmp to "Market Perform"May 17, 2025 | americanbankingnews.comOppenheimer Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00May 17, 2025 | americanbankingnews.comPiper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $7.00May 17, 2025 | americanbankingnews.comTruist Financial Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $10.00May 17, 2025 | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Stock Rating Lowered by Citizens JmpCitizens Jmp downgraded shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday.May 16, 2025 | marketbeat.comRobert W. Baird Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock PriceRobert W. Baird lowered their price objective on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating for the company in a research note on Wednesday.May 16, 2025 | marketbeat.comPatient Square Capital LP Makes New $3.17 Million Investment in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Patient Square Capital LP bought a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,489,909 shares of the company's stock, valued at approxiMay 16, 2025 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Earns Outperform Rating from Royal Bank of CanadaMay 16, 2025 | americanbankingnews.comRobert W. Baird Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00May 16, 2025 | americanbankingnews.comAllogene Therapeutics falls after trial delay, rating downgrade post Q1 resultsMay 15, 2025 | msn.comAllogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentumMay 14, 2025 | msn.comAllogene Therapeutics Reports First Quarter 2025 Financial Results and Business UpdateMay 14, 2025 | finance.yahoo.comAllogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comAllogene Therapeutics Reports First Quarter 2025 Financial Results and Business UpdateMay 13, 2025 | globenewswire.comDimensional Fund Advisors LP Raises Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Dimensional Fund Advisors LP lifted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 30.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,561,626 shares of the company's stock after buyingMay 13, 2025 | marketbeat.com6ALLO : Allogene Therapeutics's Earnings OutlookMay 12, 2025 | benzinga.comAllogene Therapeutics (ALLO) to Release Quarterly Earnings on MondayMay 11, 2025 | americanbankingnews.comIs Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | uk.finance.yahoo.com10 Low Risk High Reward Stocks Set to Triple by 2030May 9, 2025 | insidermonkey.comSynnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of DirectorsMay 8, 2025 | finance.yahoo.comAllogene Therapeutics Inc.May 7, 2025 | barrons.comAllogene Therapeutics Inc.May 7, 2025 | barrons.comAllogene Therapeutics (ALLO) Projected to Post Earnings on MondayAllogene Therapeutics (NASDAQ:ALLO) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-allogene-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comAllogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business UpdateMay 6, 2025 | globenewswire.comPrice T Rowe Associates Inc. MD Sells 353,171 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Price T Rowe Associates Inc. MD reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 7.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,485,572 shares of the company's stock after selling 353,171 shares during the qMay 6, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Invests $802,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Susquehanna Fundamental Investments LLC purchased a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 376,661 shares of the company's stock, valueMay 5, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from BrokeragesAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buMay 5, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Bought by Barclays PLCBarclays PLC boosted its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 122.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 761,286 shares of the company's stock after purchasing an additional 418,313 shaMay 5, 2025 | marketbeat.com3,448,275 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Bought by Foresite Capital Management VI LLCForesite Capital Management VI LLC bought a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,448,275 shares of the company's stock, valuedApril 30, 2025 | marketbeat.comLynx1 Capital Management LP Buys 4,672,349 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Lynx1 Capital Management LP lifted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 75.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,874,723 shares of thApril 29, 2025 | marketbeat.comXTX Topco Ltd Buys Shares of 158,537 Allogene Therapeutics, Inc. (NASDAQ:ALLO)XTX Topco Ltd acquired a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 158,537 shares of the company's stock, valued at approximately $338,00April 26, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59%April 25, 2025 | finance.yahoo.comAnnie Yoshiyama Sells 9,601 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) StockApril 24, 2025 | insidertrades.comAllogene Therapeutics to present updated ALLO-316 results at ASCO meetingApril 24, 2025 | markets.businessinsider.comCentury Therapeutics (IPSC) Gets a Hold from William BlairApril 23, 2025 | markets.businessinsider.comAllogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comGilead Sciences Inc. Purchases New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Gilead Sciences Inc. acquired a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,156,689 shares of the company'sApril 20, 2025 | marketbeat.comJPMorgan Chase & Co. Reduces Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)JPMorgan Chase & Co. cut its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 8.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,736,132 shares of the company's stock afterApril 19, 2025 | marketbeat.comVanguard Group Inc. Trims Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Vanguard Group Inc. cut its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,000,692 shares of the companApril 19, 2025 | marketbeat.comWilliam Blair Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)April 10, 2025 | markets.businessinsider.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by AnalystsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have giApril 9, 2025 | marketbeat.comAllogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and ...April 9, 2025 | seekingalpha.comAllogene Therapeutics granted three Fast Track Designations for ALLO-329April 8, 2025 | markets.businessinsider.comZacks Research Analysts Increase Earnings Estimates for ALLOAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for Allogene Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst R. Department now expects that the company will post earnings oApril 8, 2025 | marketbeat.comAllogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and SclerodermaApril 7, 2025 | globenewswire.com Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Media Mentions By Week ALLO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLO News Sentiment▼0.040.65▲Average Medical News Sentiment ALLO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLO Articles This Week▼254▲ALLO Articles Average Week Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NTLA News Today RCUS News Today AVDL News Today SYRE News Today PHVS News Today CVAC News Today CRMD News Today BCAX News Today ELVN News Today ZYME News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALLO Stock Free ALLO Stock Alerts